Inability of dimethyl sulfoxide to increase brain uptake of water-soluble compounds: implications to chemotherapy for brain tumors.
There is conflicting evidence as to whether dimethyl sulfoxide (DMSO) can reversibly open the blood-brain barrier and augment brain uptake of water-soluble compounds, including anticancer agents. To investigate this, 125I-human serum albumin, horseradish peroxidase, or the anticancer drug melphalan was administered iv to rats or mice, either alone or in combination with DMSO. Some animals received an additional ip priming dose of DMSO. The regional brain concentrations of each substance were measured after the animals were killed. DMSO administration did not significantly increase the brain uptake of any of the compounds as compared to control uptakes. These results do not support prior reports that DMSO increases the permeability of water-soluble agents across the blood-brain barrier.
D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001921:Brain / Q000378:metabolism*; D001932:Brain Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004121:Dimethyl Sulfoxide / Q000494:pharmacology*; D006735:Horseradish Peroxidase; D006801:Humans; D008297:Male; D008558:Melphalan / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D009994:Osmolar Concentration; D051381:Rats; D011916:Rats, Inbred F344; D011919:Rats, Inbred Strains; D012709:Serum Albumin / Q000378:metabolism; D012995:Solubility
D012709:Serum Albumin; D006735:Horseradish Peroxidase; D008558:Melphalan; D004121:Dimethyl Sulfoxide